On January 5, 2016, MannKind Corporation announced the termination of its license and collaboration agreement with Sanofi-Aventis, for development and commercialization of Afrezza, hoping for a smooth transition back to MannKind through the next 6 months. You can read the story, as reported by DiaTribe on January 11, 2016, here. http://tinyurl.com/j8x2tgb
Sad news, scary news. I’ve been using Afrezza, on an as-needed basis and to supplement my bolus insulin to account for heavy carb meals. And it works! (shown here with my Afrezza “pipe” and Bon Bon)
My new insurance formulary no longer covers Afrezza, as it did in 2015. I’ve been trying to figure out how to continue to get Afrezza, until it no longer exists.
But WAIT!
MannKind Corporation, on January 21, 2016, announced that it has entered into a collaboration and license agreement with a newly formed entity, Receptor Life Sciences, to address multiple inhaled therapeutic products in development for conditions such as chronic pain, neurologic diseases and inflammatory disorders. From the Nasdaq GlobeNewswire: http://tinyurl.com/jmqnftf
How interesting. But it is not at all clear whether Afrezza will continue to be available. Guess we’ll have to wait and see.
